Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.12 | 0.7 |
mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Sunitinib | FIMM | pan-cancer | AAC | 0.069 | 0.7 |
mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.061 | 0.7 |